A Phase 3 interventional study of ARALAST NP 60 mg/kg and ARALAST NP 120 mg/kg in Chronic Obstructive Pulmonary Disease and Alpha1-antitrypsin Deficiency, sponsored by Baxalta now part of Shire. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.
Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 958th largest by enrollment of the 1,037 interventional ones that give a count, is one of 57 that started in 2016, is one of 226 in phase 3, and was the 714th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 117 · Phase 2 230 · Phase 3 238 · Phase 4 98
First in 1994; this study’s year is marked. 57 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 100 across the 1,037 interventional studies, 171 across the 237 observational. Of the 1,018 that completed or were terminated, 502 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
603 of 1,278 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Takeda has 6 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
62 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT05879211Duke UniversityGoal Concordant Care Learning Laboratory | 2026-12 |
Add all 62 to your calendar (.ics) → With an account.
Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic obstructive pulmonary disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Smoker or participant that has ceased smoking for less than one year prior to screening whose levels of cotinine are outside of the normal range of a nonsmoker.
All participants must agree to refrain from smoking throughout the course of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg/kg body weight/week
Biological: ARALAST NP 60 mg/kg
120 mg/kg body weight/week
Biological: ARALAST NP 120 mg/kg
60 mg/kg body weight/week
Biological: GLASSIA 60 mg/kg
120 mg/kg body weight/week
Biological: GLASSIA 120 mg/kg
Human Albumin 2%
Biological: Human Albumin 2%
Drug page: Alpha 1-Antitrypsin
ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Also known as: Alpha1-Proteinase Inhibitor (Human), A1PI, Alpha1-Proteinase Inhibitor
Drug page: Alpha 1-Antitrypsin
ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), A1PI
Drug page: Alpha 1-Antitrypsin
GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Also known as: Alpha1-Proteinase Inhibitor (Human), A1PI, Alpha1-Proteinase Inhibitor
Drug page: Alpha 1-Antitrypsin
GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), A1PI
Human albumin 2% (by appropriate dilution with normal saline solution)
Rate of Change in Lung Density Based on Group 1 (ARALAST NP) Versus Placebo, Group 3 and Group 4 (GLASSIA) Versus Placebo
Rate of change in lung density was assessed by computed tomography (CT) densitometry. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. CT lung density at the 15th percentile (PD15) is the threshold below which 15% of the voxels have lower densities, and was used as the parameter for estimating the rate of lung density decline. Rate of change in lung density based on Group 1 (ARALAST NP) versus Placebo, Group 3 and Group 4 (GLASSIA) versus Placebo were reported. The safety analysis set used for all the efficacy parameter assessment.
Time frame: Baseline, Early termination of the study (approximately 22 months)
Rate of Change in Lung Density for Each Treatment Group
Rate of change in lung density was assessed by computed tomography (CT) densitometry for each treatment group. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. The safety analysis set used for all the efficacy parameter assessment.
Time frame: Baseline, Early termination of the study (approximately 22 months)
Mean Steady State Trough Concentration of Antigenic and Functional Alpha1-Proteinase Inhibitor (A1PI) for ARALAST NP and GLASSIA at Each Dose Level
Mean steady state trough concentration of antigenic and functional alpha1-proteinase inhibitor (a1pi) for ARALAST NP and GLASSIA at each dose level was reported.
Time frame: Baseline, Early termination of the study (approximately 22 months)
Number of Events With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Event (TEAE)
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. TEAE related to Investigational Product (IP) and Study Procedures (SP) were considered. A non-serious AE is an AE that does not meet the criteria of an SAE. Number of events with related and unrelated serious and non-serious TEAE were reported.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Percentage of Participants With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Events (TEAE's)
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAE related to IP and Study Procedures were considered. Percentage of participants with related and unrelated serious and non-serious TEAE were reported.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Number of Events With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Percentage of Participants With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Number of Events With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)
An Adverse Reactions (ARs) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Percentage of Participants With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)
An Adverse Reactions (AR) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Percentage of Participants With at Least One Infusion Rate Change or Infusion Interruption or Stopped Due to AEs
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Number of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to adverse events (AEs) were reported.
Time frame: From start of study treatment up to early termination of the study (approximately 22 months)
Number of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA
Number of participants who developed anti- A1PI antibodies following treatment with ARALAST NP or GLASSIA were reported. Anti-A1PI binding antibody were determined for the samples that tested positive or negative at each assessment time point.
Time frame: Baseline, Early termination of the study (approximately 22 months)
The study was conducted at 4 study centers in the United States (3) and Australia (1) between 02 November 2016 (first participant first visit) and 14 September 2018 (last participant last visit).
| Milestone | ARALAST NP 60 mg/kg (Group 1) | ARALAST NP 120 mg/kg (Group 2) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|---|
| Started | 1 | 0 | 2 | 2 | 2 |
| Treated | 1 | 0 | 1 | 1 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 2 | 2 | 2 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 2 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 1 |
Rate of change in lung density was assessed by computed tomography (CT) densitometry. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. CT lung density at the 15th percentile (PD15) is the threshold below which 15% of the voxels have lower densities, and was used as the parameter for estimating the rate of lung density decline. Rate of change in lung density based on Group 1 (ARALAST NP) versus Placebo, Group 3 and Group 4 (GLASSIA) versus Placebo were reported. The safety analysis set used for all the efficacy parameter assessment.
No measurements were reported for this outcome.
Rate of change in lung density was assessed by computed tomography (CT) densitometry for each treatment group. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. The safety analysis set used for all the efficacy parameter assessment.
No measurements were reported for this outcome.
Mean steady state trough concentration of antigenic and functional alpha1-proteinase inhibitor (a1pi) for ARALAST NP and GLASSIA at each dose level was reported.
No measurements were reported for this outcome.
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. TEAE related to Investigational Product (IP) and Study Procedures (SP) were considered. A non-serious AE is an AE that does not meet the criteria of an SAE. Number of events with related and unrelated serious and non-serious TEAE were reported.
| Events | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Serious TEAE: Events Related to IP | 0 | 0 | 0 | 0 |
| Non-serious TEAE: Events Related to IP | 0 | 0 | 0 | 19 |
| Serious TEAE: Events Related to SP | 0 | 0 | 0 | 0 |
| Non-serious TEAE: Events Related to SP | 0 | 0 | 0 | 1 |
| Serious TEAE: Unrelated Events | 0 | 0 | 0 | 0 |
| Non-serious TEAE: Unrelated Events | 2 | 0 | 0 | 5 |
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAE related to IP and Study Procedures were considered. Percentage of participants with related and unrelated serious and non-serious TEAE were reported.
| Percentage of Participants | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Serious TEAE: Related to IP | 0 | 0 | 0 | 0 |
| Non-Serious TEAE: Related to IP | 0 | 0 | 0 | 50 |
| Serious TEAE: Related to SP | 0 | 0 | 0 | 0 |
| Non-Serious TEAE: Related to SP | 0 | 0 | 0 | 50 |
| Serious TEAE: Unrelated | 0 | 0 | 0 | 0 |
| Non-Serious TEAE: Unrelated | 100 | 0 | 0 | 100 |
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.
| Events | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Temporally Serious TEAE Related to IP | 0 | 0 | 0 | 0 |
| Temporally Non-Serious TEAE Related to IP | 0 | 0 | 0 | 17 |
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.
| Percentage of Participants | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Temporally Serious TEAE Related to IP | 0 | 0 | 0 | 0 |
| Temporally Non-Serious TEAE Related to IP | 0 | 0 | 0 | 50 |
An Adverse Reactions (ARs) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.
| Events | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Suspected ARs or Non-serious ARs | 1 | 0 | 0 | 24 |
| Suspected ARs or Serious ARs | 0 | 0 | 0 | 0 |
An Adverse Reactions (AR) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.
| Percentage of Participants | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Suspected ARs or Non-serious ARs | 100 | 0 | 0 | 50 |
| Suspected ARs or Serious ARs | 0 | 0 | 0 | 0 |
An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Number of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to adverse events (AEs) were reported.
| Percentage of Participants | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Participants with at Least 1 Infusion Rate Change | 0 | 0 | 0 | 50 |
| Participantswith at Least 1 Infusion Interruption | 0 | 0 | 0 | 50 |
Number of participants who developed anti- A1PI antibodies following treatment with ARALAST NP or GLASSIA were reported. Anti-A1PI binding antibody were determined for the samples that tested positive or negative at each assessment time point.
| Participants | ARALAST NP 60 mg/kg (Group 1) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|
| Number of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA | 0 | 0 | 0 | 0 |
Collected over From start of study treatment up to early termination of the study (approximately 22 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARALAST NP 60 mg/kg (Group 1) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| ARALAST NP 120 mg/kg (Group 2) | — | — | — |
| GLASSIA 60 mg/kg (Group 3) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| GLASSIA 120 mg/kg (Group 4) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Placebo (Group 5) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | ARALAST NP 60 mg/kg (Group 1) | ARALAST NP 120 mg/kg (Group 2) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) |
|---|---|---|---|---|---|
| Right Eye Retinal DetachmentEye disorders | 1/1 | — | 0/1 | 0/1 | 0/2 |
| DIARRHOEAGastrointestinal disorders | 1/1 | — | 0/1 | 0/1 | 0/2 |
| HeadacheNervous system disorders | 0/1 | — | 0/1 | 0/1 | 1/2 |
| NauseaNervous system disorders | 0/1 | — | 0/1 | 0/1 | 1/2 |
| CONTACT DERMATITISSkin and subcutaneous tissue disorders | 0/1 | — | 0/1 | 0/1 | 1/2 |
| site conditions/ Catheter site rash/ MILD RASH AT THE SITE OF TAPE USED AT IV CANNULA SITEGeneral disorders | 0/1 | — | 0/1 | 0/1 | 1/2 |
| Vaginal haemorrhage/ PER VAGINAL BLEEDINGReproductive system and breast disorders | 0/1 | — | 0/1 | 0/1 | 1/2 |
| Chronic obstructive pulmonary disease/ COPD EXACERBATIONRespiratory, thoracic and mediastinal disorders | 0/1 | — | 0/1 | 0/1 | 1/2 |
Safety Analysis Set (SAS) included all participants who had received any amount of investigational product (IP) or placebo, regardless of protocol deviations or non-adherence to the study procedures. Analysis was performed according to the treatment regimen received regardless of the randomized treatment regimen.
| Age, Continuous(Years) | ARALAST NP 60 mg/kg (Group 1) | ARALAST NP 120 mg/kg (Group 2) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) | Total |
|---|---|---|---|---|---|---|
| Mean | 62.0 ± NA | — | 65.0 ± NA | 68.0 ± NA | 46.0 ± 4.24 | 57.4 ± 10.83 |
| Sex: Female, Male(Participants) | ARALAST NP 60 mg/kg (Group 1) | ARALAST NP 120 mg/kg (Group 2) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) | Total |
|---|---|---|---|---|---|---|
| Female | 1 | — | 1 | 1 | 2 | 5 |
| Male | 0 | — | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | ARALAST NP 60 mg/kg (Group 1) | ARALAST NP 120 mg/kg (Group 2) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | — | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | — | 1 | 1 | 2 | 5 |
| Unknown or Not Reported | 0 | — | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ARALAST NP 60 mg/kg (Group 1) | ARALAST NP 120 mg/kg (Group 2) | GLASSIA 60 mg/kg (Group 3) | GLASSIA 120 mg/kg (Group 4) | Placebo (Group 5) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | — | 0 | 0 | 0 | 0 |
| Asian | 0 | — | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | — | 0 | 0 | 0 | 0 |
| Black or African American | 0 | — | 0 | 0 | 0 | 0 |
| White | 1 | — | 1 | 1 | 2 | 5 |
| More than one race | 0 | — | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | — | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants).
Ran from Nov 2016 to primary completion in Sep 2018, 22 months.
Results were first posted in Oct 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
Pulmonary Disease, Chronic Obstructive →